Identification of Phenylpyrazolone Dimers as a New Class of Anti-Trypanosoma cruzi Agents

Maarten Sijm, Julianna Siciliano de Araújo, Alba Ramos Llorca, Kristina Orrling, Lydia Stiny, An Matheeussen, Louis Maes, Iwan J.P. de Esch, Maria de Nazaré Correia Soeiro, Geert Jan Sterk, Rob Leurs

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Chagas disease is becoming a worldwide problem; it is currently estimated that over six million people are infected. The two drugs in current use, benznidazole and nifurtimox, require long treatment regimens, show limited efficacy in the chronic phase of infection, and are known to cause adverse effects. Phenotypic screening of an in-house library led to the identification of 2,2′-methylenebis(5-(4-bromophenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one), a phenyldihydropyrazolone dimer, which shows an in vitro pIC50 value of 5.4 against Trypanosoma cruzi. Initial optimization was done by varying substituents of the phenyl ring, after which attempts were made to replace the phenyl ring. Finally, the linker between the dimer units was varied, ultimately leading to 2,2′-methylenebis(5-(3-bromo-4-methoxyphenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (NPD-0228) as the most potent analogue. NPD-0228 has an in vitro pIC50 value of 6.4 against intracellular amastigotes of T. cruzi and no apparent toxicity against the human MRC-5 cell line and murine cardiac cells.

Original languageEnglish
Pages (from-to)1662-1668
Number of pages7
JournalChemMedChem
Volume14
Issue number18
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Trypanosoma cruzi
Dimers
Nifurtimox
Chagas Disease
Libraries
Toxicity
Screening
Cells
Cell Line
Infection
Pharmaceutical Preparations
In Vitro Techniques
neodymium pyrocatechin disulfonate
benzonidazole

Keywords

  • benznidazole
  • Chagas disease
  • nifurtimox
  • phenotypic screening
  • Trypanosoma cruzi

Cite this

Sijm, M., Siciliano de Araújo, J., Ramos Llorca, A., Orrling, K., Stiny, L., Matheeussen, A., ... Leurs, R. (2019). Identification of Phenylpyrazolone Dimers as a New Class of Anti-Trypanosoma cruzi Agents. ChemMedChem, 14(18), 1662-1668. https://doi.org/10.1002/cmdc.201900370
Sijm, Maarten ; Siciliano de Araújo, Julianna ; Ramos Llorca, Alba ; Orrling, Kristina ; Stiny, Lydia ; Matheeussen, An ; Maes, Louis ; de Esch, Iwan J.P. ; de Nazaré Correia Soeiro, Maria ; Sterk, Geert Jan ; Leurs, Rob. / Identification of Phenylpyrazolone Dimers as a New Class of Anti-Trypanosoma cruzi Agents. In: ChemMedChem. 2019 ; Vol. 14, No. 18. pp. 1662-1668.
@article{0fc16b36d48a4130af0817e6014afc5f,
title = "Identification of Phenylpyrazolone Dimers as a New Class of Anti-Trypanosoma cruzi Agents",
abstract = "Chagas disease is becoming a worldwide problem; it is currently estimated that over six million people are infected. The two drugs in current use, benznidazole and nifurtimox, require long treatment regimens, show limited efficacy in the chronic phase of infection, and are known to cause adverse effects. Phenotypic screening of an in-house library led to the identification of 2,2′-methylenebis(5-(4-bromophenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one), a phenyldihydropyrazolone dimer, which shows an in vitro pIC50 value of 5.4 against Trypanosoma cruzi. Initial optimization was done by varying substituents of the phenyl ring, after which attempts were made to replace the phenyl ring. Finally, the linker between the dimer units was varied, ultimately leading to 2,2′-methylenebis(5-(3-bromo-4-methoxyphenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (NPD-0228) as the most potent analogue. NPD-0228 has an in vitro pIC50 value of 6.4 against intracellular amastigotes of T. cruzi and no apparent toxicity against the human MRC-5 cell line and murine cardiac cells.",
keywords = "benznidazole, Chagas disease, nifurtimox, phenotypic screening, Trypanosoma cruzi",
author = "Maarten Sijm and {Siciliano de Ara{\'u}jo}, Julianna and {Ramos Llorca}, Alba and Kristina Orrling and Lydia Stiny and An Matheeussen and Louis Maes and {de Esch}, {Iwan J.P.} and {de Nazar{\'e} Correia Soeiro}, Maria and Sterk, {Geert Jan} and Rob Leurs",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cmdc.201900370",
language = "English",
volume = "14",
pages = "1662--1668",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "18",

}

Sijm, M, Siciliano de Araújo, J, Ramos Llorca, A, Orrling, K, Stiny, L, Matheeussen, A, Maes, L, de Esch, IJP, de Nazaré Correia Soeiro, M, Sterk, GJ & Leurs, R 2019, 'Identification of Phenylpyrazolone Dimers as a New Class of Anti-Trypanosoma cruzi Agents' ChemMedChem, vol. 14, no. 18, pp. 1662-1668. https://doi.org/10.1002/cmdc.201900370

Identification of Phenylpyrazolone Dimers as a New Class of Anti-Trypanosoma cruzi Agents. / Sijm, Maarten; Siciliano de Araújo, Julianna; Ramos Llorca, Alba; Orrling, Kristina; Stiny, Lydia; Matheeussen, An; Maes, Louis; de Esch, Iwan J.P.; de Nazaré Correia Soeiro, Maria; Sterk, Geert Jan; Leurs, Rob.

In: ChemMedChem, Vol. 14, No. 18, 01.01.2019, p. 1662-1668.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Identification of Phenylpyrazolone Dimers as a New Class of Anti-Trypanosoma cruzi Agents

AU - Sijm, Maarten

AU - Siciliano de Araújo, Julianna

AU - Ramos Llorca, Alba

AU - Orrling, Kristina

AU - Stiny, Lydia

AU - Matheeussen, An

AU - Maes, Louis

AU - de Esch, Iwan J.P.

AU - de Nazaré Correia Soeiro, Maria

AU - Sterk, Geert Jan

AU - Leurs, Rob

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chagas disease is becoming a worldwide problem; it is currently estimated that over six million people are infected. The two drugs in current use, benznidazole and nifurtimox, require long treatment regimens, show limited efficacy in the chronic phase of infection, and are known to cause adverse effects. Phenotypic screening of an in-house library led to the identification of 2,2′-methylenebis(5-(4-bromophenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one), a phenyldihydropyrazolone dimer, which shows an in vitro pIC50 value of 5.4 against Trypanosoma cruzi. Initial optimization was done by varying substituents of the phenyl ring, after which attempts were made to replace the phenyl ring. Finally, the linker between the dimer units was varied, ultimately leading to 2,2′-methylenebis(5-(3-bromo-4-methoxyphenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (NPD-0228) as the most potent analogue. NPD-0228 has an in vitro pIC50 value of 6.4 against intracellular amastigotes of T. cruzi and no apparent toxicity against the human MRC-5 cell line and murine cardiac cells.

AB - Chagas disease is becoming a worldwide problem; it is currently estimated that over six million people are infected. The two drugs in current use, benznidazole and nifurtimox, require long treatment regimens, show limited efficacy in the chronic phase of infection, and are known to cause adverse effects. Phenotypic screening of an in-house library led to the identification of 2,2′-methylenebis(5-(4-bromophenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one), a phenyldihydropyrazolone dimer, which shows an in vitro pIC50 value of 5.4 against Trypanosoma cruzi. Initial optimization was done by varying substituents of the phenyl ring, after which attempts were made to replace the phenyl ring. Finally, the linker between the dimer units was varied, ultimately leading to 2,2′-methylenebis(5-(3-bromo-4-methoxyphenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (NPD-0228) as the most potent analogue. NPD-0228 has an in vitro pIC50 value of 6.4 against intracellular amastigotes of T. cruzi and no apparent toxicity against the human MRC-5 cell line and murine cardiac cells.

KW - benznidazole

KW - Chagas disease

KW - nifurtimox

KW - phenotypic screening

KW - Trypanosoma cruzi

UR - http://www.scopus.com/inward/record.url?scp=85071317667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071317667&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201900370

DO - 10.1002/cmdc.201900370

M3 - Article

VL - 14

SP - 1662

EP - 1668

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 18

ER -

Sijm M, Siciliano de Araújo J, Ramos Llorca A, Orrling K, Stiny L, Matheeussen A et al. Identification of Phenylpyrazolone Dimers as a New Class of Anti-Trypanosoma cruzi Agents. ChemMedChem. 2019 Jan 1;14(18):1662-1668. https://doi.org/10.1002/cmdc.201900370